Press release
Dengue Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight
Explore our latest breakthroughs in Dengue Research. Learn more about our innovative pipeline today! @ Dengue Pipeline Outlook [https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Dengue Pipeline Report
* On 03 November 2025, Takeda (TSE: 4502/NYSE: TAK) today announced the successful completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) evaluating QDENGA Registered (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The long-term data reaffirm the vaccine's favorable benefit-risk profile and demonstrate that the standard two-dose regimen provides durable protection against dengue fever.
* On 27 October 2025, Merck Sharp & Dohme LLC initiated a study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
* On 24 October 2025, Island Pharmaceuticals conducted a study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and symptoms of dengue virus (DENV) infection over 29 days following subcutaneous challenge of healthy subjects with 'Dengue 1 Live Virus Human Challenge' (DENV-1-LVHC). Humoral and cellular immune responses, both innate and adaptive, circulating virus, and changes in clinical laboratory measures will also be examined.
* On 20 October 2025, AbViro LLC announced a Phase 2 study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3
* DelveInsight's Dengue pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment.
* The leading Dengue Companies such as Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals , and others.
* Promising Dengue Therapies such as EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
Stay informed about the cutting-edge advancements in Dengue Treatments. Download for updates and be a part of the revolution in infectious disease care @ Dengue Clinical Trials Assessment [https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dengue Overview
Dengue is a mosquito-transmitted virus and the leading cause of arthropod-borne viral disease in the world. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. Although most cases are asymptomatic, severe illness and death may occur. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world. The incidence of dengue has increased dramatically over the past few decades, and the infection is now endemic in some parts of the world.
Dengue Emerging Drugs Profile
* VIS 513: Visterra
VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally.
* TAK-003: Takeda
Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic "backbone" for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.
* CDX DENV: Codagenix
Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment of Dengue.
* AT 752: Atea Pharmaceuticals
AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.
The Dengue Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Dengue with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Treatment.
* Dengue Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dengue Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue market
Learn more about Dengue Drugs opportunities in our groundbreaking Dengue Research and development projects @ Dengue Unmet Needs [https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dengue Companies
Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals and others.
Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Dengue Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in Dengue Treatment by visiting our website. Stay informed about how we're transforming the future of infectious disease @ Dengue Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Dengue Pipeline Report
* Coverage- Global
* Dengue Companies- Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
* Dengue Therapies- EYU 688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV) , and others.
* Dengue Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Dengue Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Dengue Pipeline on our website @ Dengue Drugs and Companies [https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Dengue: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dengue- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* TAK-003: Takeda
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AT 752: Atea Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Dengue Key Companies
* Dengue Key Products
* Dengue- Unmet Needs
* Dengue- Market Drivers and Barriers
* Dengue- Future Perspectives and Conclusion
* Dengue Analyst Views
* Dengue Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dengue-pipeline-outlook-report-2025-promising-drugs-and-moa-innovations-reshape-future-treatment-approaches-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dengue-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dengue Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight here
News-ID: 4258181 • Views: …
More Releases from ABNewswire
Atlanta Data Center Market to Reach USD 3 Billion by 2030 Driven by Hyperscale D …
Mordor Intelligence has published a new report on the Atlanta Data Center Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Atlanta Data Center Market Overview
The Atlanta Data Center Market currently supports 0.88 GW of installed IT power and is on course to reach 2.99 GW by 2030, reflecting a vigorous 27.71% CAGR. This growth highlights the increasing Atlanta Data Center Market size, positioning the city as a…
Jeanne Player Fine Art selected for prestigious art show while expanding product …
Abstract artist Jeanne Player Fine Art secures third year participation in Spotlight on Art while growing wholesale distribution and online presence. The North Carolina artist's diverse offerings from original painting o TV downloads serve art collectors, interior designers, and gift retailers seeking colorful, elegant art for beautiful spaces.
Jeanne Player Fine Art achieves remarkable recognition in the contemporary art world with selection for the distinguished Spotlight on Art art show again…
She She's Closet Celebrates Holiday Season with Exclusive Global Artisan Collect …
Award-winning Miramar boutique She She's Closet unveils special holiday collection featuring handcrafted pieces from women artisans globally, offering unique gift options while supporting Fair Trade practices. The three-time "Best Boutique" winner brings sustainable, one-of-a-kind accessories perfect for holiday celebrations and meaningful gift-giving.
As the holiday shopping season approaches, She She's Closet, Miramar's premier destination for unique women's accessories and jewelry, is positioning itself as the go-to source for meaningful, handcrafted gifts…
MED-TAC International Launches Holiday Campaign to Transform First-Aid Kits into …
MED-TAC International Corp. announces a holiday initiative to help families, schools, and agencies upgrade from basic first-aid kits to comprehensive emergency response capabilities. The program combines evidence-aligned medical gear with ready-to-teach training modules, ensuring communities can act effectively in the critical moments before EMS arrives.
As families gather for the holidays and organizations prepare for year-end safety reviews, MED-TAC International Corp. is revolutionizing how communities approach emergency preparedness with their innovative…
More Releases for Dengue
Key Trend Reshaping the Dengue Treatment Market in 2025: Innovative Drug Deliver …
Which drivers are expected to have the greatest impact on the over the dengue treatment market's growth?
The escalation in cases of dengue is projected to stimulate the expansion of the market for dengue treatments. Dengue is a viral infection transmitted by mosquito bites, causing symptoms akin to the flu and can escalate to intense complications if not treated. The escalation is primarily due to progressing urbanization, climate alterations favourable to…
Key Dengue Vaccine Market Trend for 2025-2034: Advancements In Dengue Tetravalen …
What Is the Future Outlook for the Dengue Vaccine Market's Size and Growth Rate?
In the past few years, the dengue vaccine market has experienced significant growth. From $0.64 billion in 2024, it is projected to reach $0.72 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%. This notable expansion during the historical period can be credited to factors such as an increase in travel and urbanization trends,…
Dengue Vaccine Market : An Detailed Overview
Introduction:
Dengue fever is a mosquito-borne viral infection caused by the dengue virus, transmitted primarily through Aedes aegypti and Aedes albopictus mosquitoes. Affecting millions globally each year, dengue has become a significant public health concern, especially in tropical and subtropical regions. The development of dengue vaccines represents a groundbreaking advancement in preventing the disease, reducing its associated healthcare costs, and controlling outbreaks. With increasing awareness and investments in immunization programs, the…
Dengue Vaccine Market : An Overview
Introduction:
Dengue fever is a mosquito-borne viral infection that has become a significant public health challenge in tropical and subtropical regions. The disease is caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. With approximately 390 million infections annually, dengue fever places a substantial burden on healthcare systems and economies worldwide. Efforts to mitigate this burden have led to the development of dengue vaccines, designed to prevent…
"Rising Incidence of Dengue Fever Propels Dengue Virus Diagnostic Tests Market T …
According to WHO, dengue affects about 50-100 million people worldwide, annually. It is a vector-borne highly communicable disease. This report discusses the diagnostic tests used to confirm the presence of dengue in one individual.
It is true that the growth of the global dengue virus diagnostic tests market is primarily driven by an increase in the incidence of dengue fever, which is a mosquito-borne viral infection that can cause severe flu-like…
Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240
The report provides a comprehensive analysis of company profiles listed below:
- Sanofi
- Takeda
Dengue Vaccines Market Segment by…
